SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
VAN LUNSEN GIL J

(Last) (First) (Middle)
C/O ARRAY BIOPHARMA INC.
3200 WALNUT STREET

(Street)
BOULDER CO 80301

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARRAY BIOPHARMA INC [ ARRY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2018
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/15/2018 M 7,000 A $5.95 26,297 D
Common Stock 08/15/2018 M 14,500 A $5.6 40,797 D
Common Stock 08/15/2018 S(1) 21,500 D $13.92 19,297 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $5.95 08/15/2018 M 7,000 (2) 10/27/2026 Common Stock 7,000 $0.00 18,000 D
Stock Option (Right to Buy) $5.6 08/15/2018 M 14,500 (3) 10/23/2023 Common Stock 14,500 $0.00 0.00 D
Explanation of Responses:
1. These trades were made pursuant to a Rule 10b5-1 trading plan.
2. Options vested on October 27, 2017.
3. Options vested on October 23, 2014.
Remarks:
Jason Haddock, attorney-in-fact for Gil Van Lunsen 08/17/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Power of Attorney

The undersigned constitutes and appoints John R. Moore and Jason Haddock, and
each of them, as his true and lawful attorney-in-fact and agent, with the full
power of substitution and resubstitution, from the undersigned and in the
undersigned and in the undersigned's behalf of all Forms 3, 4 and 5 (including)
any amendments thereto) that the undersigned may be required to file with the
U.S. Securities and Exchange Commission as a result of the undersigned's
ownership of or transactions in securities of Array BioPharma Inc. The Authority
of John R. Moore and Jason Haddock under this statement shall continue until the
undersigned is no longer required to file Forms 3, 4 and 5 with regard to the
undersigned's ownership of or transactions in securities of Array BioPharma Inc
unless earlier revoked in writing. The undersigned acknowledges that neither
John R. Moore nor Jason Haddock is assuming any of the undersigned's
responsibilities to comply with Section 16 of the Section 16 of the Securities
Exchange Act of 1934.
Dated: April 27, 2017

/s/ Gil J. Van Lusen